Boehringer Ingelheim India has entered into strategic alliances for diabetes management in India by partnering with Lupin Ltd and Torrent Pharma Ltd. for the sale and co-marketing of Boehringer Ingelheim’s Empagliflozin, Linagliptin and its combination products. These partnerships reaffirms our commitment towards addressing challenges in diabetes management by enabling improved access to innovative medicine in India. With the help of our commercial partnerships, Boehringer Ingelheim has transformed the lives of 2mn+ patients every year. Through its research and scientific excellence, Boehringer Ingelheim India will continue to introduce innovative products and bring together the healthcare ecosystem to address the unmet medical needs.
